Results 291 to 300 of about 914,658 (345)

Editorial: Advanced approaches in pediatric clinical pharmacology. [PDF]

Front Pharmacol
Al-Sallami H, Diniz A, Sinha J, Karatza E, Allegaert K.   +4 more
europepmc   +1 more source

Clinical Pharmacology and Therapeutics for Veterinary Technicians

, 2016
Robert L. Bill
openalex   +1 more source

Ethics for artificial intelligence use in clinical pharmacology.

Indian J Pharmacol
Kleebayoon A, Wiwanitkit V.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Geriatric Clinical Pharmacology

Cardiology Clinics, 1986
Age-related physiologic changes may significantly alter drug disposition and dynamics in the elderly. This is especially important for cardiovascular drugs, because they are used with such high frequency in the geriatric population. Alterations in the pharmacokinetics and pharmacodynamics of several drugs used to treat cardiovascular disease have been ...
M L, Rocci, P H, Vlasses, W B, Abrams
openaire   +2 more sources

Clinical Pharmacology

JAMA: The Journal of the American Medical Association, 1989
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire   +5 more sources

Clinical Pharmacology of Inodilators

Journal of Cardiovascular Pharmacology, 1989
Recent advances in our knowledge of heart failure have shown that both a central and a peripheral factor are involved in this syndrome. Therefore, the ideal drug should combine the properties of a positive inotropic agent with those of a peripheral vasodilator; many drugs recently introduced into clinical practice have been shown to present both of ...
DEI CAS, Livio, METRA, Marco, VISIOLI, Odoardo   +2 more
openaire   +3 more sources

Clinical Pharmacology of Cilazapril

Drugs, 1989
In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.
C H, Kleinbloesem, P, Van Brummelen, R J, Francis, U W, Wiegand   +3 more
openaire   +3 more sources

Investigative Clinical Pharmacology

Clinical Pharmacology & Therapeutics, 2011
Clinical pharmacology is an essential discipline in the development of new medicines, but the closely specified requirements of pharmaceutical industry protocols and regulatory reviewers have limited the opportunities for curiosity-driven research. Realization is growing that there is so much that is not known about the mechanisms underlying human ...
openaire   +2 more sources